These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

668 related items for PubMed ID: 24309205

  • 1. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M, Muesser P, Girsberger S, Skoda R, Tzankov A, Buser A, Passweg J, Tsakiris DΑ.
    Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
    [Abstract] [Full Text] [Related]

  • 2. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
    Medinger M, Tzankov A, Kern J, Pircher A, Hermann M, Ott HW, Gastl G, Untergasser G, Gunsilius E.
    Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
    [Abstract] [Full Text] [Related]

  • 3. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [Abstract] [Full Text] [Related]

  • 4. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [Abstract] [Full Text] [Related]

  • 5. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 6. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
    Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, Dirnhofer S, Tichelli A, Tzankov A.
    Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
    [Abstract] [Full Text] [Related]

  • 7. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [Abstract] [Full Text] [Related]

  • 8. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [Abstract] [Full Text] [Related]

  • 9. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Sep; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 10. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [Abstract] [Full Text] [Related]

  • 11. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS, Kim YK, Jung SI, Jung HR, Chung IS.
    Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
    [Abstract] [Full Text] [Related]

  • 12. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.
    J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568
    [Abstract] [Full Text] [Related]

  • 13. Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms.
    Forte D, Fanelli F, Mezzullo M, Barone M, Corradi G, Auteri G, Bartoletti D, Martello M, Ottaviani E, Terragna C, Curti A, Pagotto U, Palandri F, Cavo M, Catani L.
    Int J Mol Sci; 2020 May 11; 21(9):. PubMed ID: 32403407
    [Abstract] [Full Text] [Related]

  • 14. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr 11; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 15. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct 11; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 16. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.
    Panova-Noeva M, Marchetti M, Spronk HM, Russo L, Diani E, Finazzi G, Salmoiraghi S, Rambaldi A, Barbui T, Ten Cate H, Falanga A.
    Am J Hematol; 2011 Apr 11; 86(4):337-42. PubMed ID: 21442635
    [Abstract] [Full Text] [Related]

  • 17. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A, French Group of Familial Myeloproliferative Disorders.
    Blood Cells Mol Dis; 2011 Apr 11; 49(3-4):170-6. PubMed ID: 22818858
    [Abstract] [Full Text] [Related]

  • 18. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
    Macedo LC, de Cesare Quintero F, Pagliari-E-Silva S, Pagnano KB, Rodrigues C, de Alencar JB, Sell AM, Visentainer JE.
    Blood Cells Mol Dis; 2016 Mar 11; 57():54-7. PubMed ID: 26852656
    [Abstract] [Full Text] [Related]

  • 19. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP, Bănescu C, Tevet M, Bojan A, Dima D, Urian L, Török-Vistai T, Popov VM, Zdrenghea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Pătrinoiu O, Balea M, Costache R, Coleș E, Șaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA.
    Br J Haematol; 2016 Jul 11; 174(2):218-26. PubMed ID: 27061303
    [Abstract] [Full Text] [Related]

  • 20. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
    Boveri E, Passamonti F, Rumi E, Pietra D, Elena C, Arcaini L, Pascutto C, Castello A, Cazzola M, Magrini U, Lazzarino M.
    Br J Haematol; 2008 Jan 11; 140(2):162-8. PubMed ID: 18028479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.